The U.S. Supreme Court heard arguments on April 27, 2026, regarding whether federal approval of glyphosate shields Bayer from cancer lawsuits [1].

The ruling could determine the fate of a multibillion-dollar wave of claims [3] and decide if the Environmental Protection Agency's (EPA) approval of the herbicide preempts state-law claims [1].

At the center of the legal battle is Roundup, a widely used weedkiller containing glyphosate. More than 100,000 cancer lawsuits have been filed against Bayer over the product [3]. The company said that because the federal government approved the active ingredient, it should not be held liable under state laws for alleged health risks.

If the court rules in favor of Bayer, it could block thousands of existing and future lawsuits [2]. This would fundamentally change how federal regulatory approvals interact with consumer litigation in the U.S. court system.

Justices appeared split during the proceedings in Washington, D.C. [2]. The core question is whether the EPA's safety determinations act as a legal shield, effectively preventing plaintiffs from arguing in state courts that the product caused their illness despite federal approval.

Bayer continues to face significant financial pressure from the ongoing litigation. The outcome of this case will establish a precedent for other chemical and pharmaceutical companies whose products have received federal clearance but face state-level liability for health complications [3].

“More than 100,000 cancer lawsuits have been filed against Bayer over Roundup”

This case addresses the legal doctrine of federal preemption. If the Supreme Court decides that EPA approval overrides state-law claims, it would create a powerful legal shield for companies whose products are federally regulated. This would likely reduce the volume of mass tort litigation against chemical manufacturers and shift the burden of safety oversight almost entirely to federal agencies.